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Purpose: PCR is widely used for rapidly and accurately detecting Mycobacterium 
species. The purpose of this study was to assess the diagnostic performance of 
three real-time PCR kits and evaluate the concordance with two older PCR meth-
ods. Materials and Methods: Using 128 samples, the five PCR methods were as-
sessed, including an in-house PCR protocol, the COBAS Amplicor MTB, the CO-
BAS TaqMan MTB, the AdvanSure TB/NTM real-time PCR, and the Real-Q M. 
tuberculosis kit. The discrepant results were further examined by DNA sequencing 
and using the AdvanSure Mycobacteria Genotyping Chip for complete analysis. 
Results: For Mycobacterium tuberculosis (MTB) detection, all five kits showed 
100% matching results (positive; N = 11 and negative; N = 80). In non-tubercu-
lous mycobacterium (NTM) discrimination, the AdvanSure yielded two true-posi-
tive outcomes from M. intracellulare and one false positive outcome, while the 
Real-Q resulted in one true-positive outcome and one false negative outcome for 
each case and another false negative result using the provided DNA samples. Con-
clusion: Real-time PCR, yielded results that were comparable to those of the older 
PCR methods for detecting MTB. However, there were disagreements among the 
applied kits in regard to the sample test results for detecting NTM. Therefore, we 
recommend that additional confirmatory measures such as DNA sequencing 
should be implemented in such cases, and further research with using a larger 
numbers of samples is warranted to improve the detection of NTM.
Key Words:    Mycobacterium tuberculosis, non-tuberculous mycobacterium, real-
time PCR
INTRODUCTION
Tuberculosis (TB) is a major global public health problem and one of the leading 
infectious causes of death. According to a recent WHO report, 1.6 million people 
worldwide died of TB in 2005.1 Korea has shown a higher prevalence of myco-
bacterial infection than most of the other developed countries, and the prevalence 
of non-tuberculous mycobacterium (NTM) infection has increased in the devel-
oped countries.2 Therefore, an increased emphasis has currently been placed on the 
rapid identification of Mycobacterium tuberculosis (MTB) and NTM.2,3
The introduction of the nucleic acid amplification techniques has been one of the Sun Young Cho, et al.
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Seoul, Korea from September 2009 to October 2009, using 
91 clinical specimens and 37 provided DNA samples (Table 
1). The clinical specimens contained pulmonary and extra-
pulmonary specimens, and the smear positive and negative 
specimens (Table 2). The specimens were stored at - 70°C in 
the state of extracted DNA. 
Specimen Preparation and DNA Separation
In-house PCR, the AdvanSure TB/NTM real-time PCR kit 
(LG Lifescience, Seoul, Korea), and the Real-Q M. tubercu-
losis kit (Biosewoom, Seoul, Korea)
After mixing 3 mL of the specimen sample with an equal 
amount of 1N NaOH, the samples were vortexed for 30 sec-
onds and then left at room temperature for 15 minutes. Subse-
quently, the mixture was centrifuged for 20 minutes at 3,000 
rpm. After discarding the supernatant, the pellet was mixed 
with 1 mL of a buffer, vortexed and centrifuged for 5 minutes 
at 7,000 rpm. This process was repeated three times. Once the 
supernatant was completely removed, the pellet was dissolved 
in an adequate amount (50-200 μL) of 5% Chelex100 with a 
major developments in diagnosis of mycobacterium, and re-
al-time PCR has recently been proposed for the detection.4 
Real-time PCR has several advantages, such as a short turn-
around time, a low contamination rate due to the use of a 
closed system and the ability to quantify the bacterial load.4,5 
In Korea, two real-time PCR kits that simultaneously detect 
MTB and NTM have been developed for rapid MTB detec-
tion and NTM discrimination. However, it is unclear whether 
these real-time PCR kits offer the same sensitivity and speci-
ficity as conventional PCR. In this study, we evaluated the di-
agnostic performance of three real-time PCR kits, by com-
paring the results from these kits with those from our in-
house PCR and the conventional qualitative PCR techniques. 
The discrepant results were confirmed by DNA sequencing 
and genotyping chip analyses. 
MATERIALS AND METHODS
Subjects
This study was conducted at Kyung Hee Medical Center, 
Table 1. The Kinds of Mycobacterium Species in NTM DNA Specimens 
Serial No. Species Serial No. Species Serial No. Species
  1 M. tuberculosis 13 M. gordonae 25 M. malmoense
  2 M. africanum 14 M. kansasii 26 M. vaccae
  3 M. simiae 15 M. celatum 27 M. fortuitum other
  4 M. avium 16 M. fortuitum 28 M. gastri
  5 M. intracellulare 17 M. peregrinum 29 M. phlei
  6 M. scrofulaceum 18 M. marinum 30 M. flavescen
  7 M. szulgai 19 M. senegalense 31 M. kansasii other 1
  8 M. terrae complex 20 M. mucogenicum 32 M. chimera
  9 M. non-chromogenicum 21 M. ulcerans 33 M. kansasii other 2
10 M. lentiflavum 22 M. asiaticum 34 Nocardia farcinica
11 M. chelonae 23 M. xenopi 35 Rhodococcus sp.
12 M. abscessus 24 M. smegmatis 36 Nocardia asteroides
37 Rhodococcus equi
NTM, non-tuberculous mycobacterium.
Table 2. The Composition of Clinical Specimens 
MTB PCR†
Positive Negative Total
Pulmonary specimen
10 72 82
SP 9 SP 52
  BW 1   BW 20
Extrapulmonary specimen*   1   8   9
Total 11 80 91
MTB, Mycobacterium tuberculosis; SP, sputum; BW, bronchial washing.
*Blood, body fluid, urine and tissue.
†5 MTB PCR results show complete concordant results; in-house PCR protocol, the COBAS Amplicor MTB, the COBAS TaqMan MTB, 
the AdvanSure TB/NTM real-time PCR, the Real-Q M. tuberculosis kit. 3 Real-Time PCR Kits for Mycobacterium
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sample was determined to be positive if absorbance was 
equal to or greater than 0.35. In addition, the COBAS Taq-
Man MTB (Roche, Branchburg, NJ, USA) was used with 
the COBAS TaqMan 48 Analyzer (Roche), the AdvanSure 
TB/NTM real-time PCR kit (LG Lifescience, Seoul, Ko-
rea) with the SLAN real-time PCR detection system (LG 
Lifescience), and the Real-Q M. tuberculosis kit (Biose-
woom, Seoul, Korea) with the Rotor-Gene Q (Corbett Life 
Science, Sydney, Australia), for the real-time PCR analysis. 
The approaches to inconsistent results
To solve inconsistent results, the 16S-23S internal tran-
buffer. The sample was then boiled for 10 minutes and centri-
fuged for 5 minutes at 12,000 rpm. In the final supernatant, 
1-2 μL was taken for the PCR reaction.
The COBAS Amplicor Mycobacterium tuberculosis test and 
the COBAS TaqMan MTB (Roche Diagnostics, Branchburg, 
NJ, USA)
One hundred μL of the prepared sample was added to 500 
μL of Respiratory Specimen Wash Solution, and this was 
centrifuged for 10 minutes at 12,500 rpm. After removing 
the supernatant, 100 μL of Respiratory Specimen Lysis So-
lution was added and this was vortexed until the pellet was 
dissolved. The sample was incubated for 45 minutes at 
60°C, and then 100 μL of Respiratory Specimen Neutral-
ization Solution was added. Using 50 μL of this reaction 
mixture with a 50 μL master mix, a PCR reaction was con-
ducted in a reaction tube.
PCR reactions
The primer sequences used for in-house PCR have previ-
ously been described.4 The in-house PCR products were 
determined to be positive if there was a 285 bp-sized band 
on the gel electrophoresis (Fig. 1). Using the IS6110 prim-
er, nested PCR was conducted using the GeneAmp PCR 
system 9600 (Perkin Elmer, CT, USA). For the COBAS 
Amplicor, which is based on the PCR-hybridization meth-
od, Amplicor (Roche Molecular Systems) was used and the 
Fig. 2. Two discrepant cases reaffirmed by sequencing and using the AdvanSure Mycobacteria Genotyping Chip (LG Life science, Seoul, 
Korea). (A) For 37 DNA samples provided, the AdvanSure kit detected all mycobacterial species and Real-Q kit showed a negative result 
for M. lentiflavum (target sequence; IS6110 region). (B) In contrast with the one false positive result from the AdvanSure kit, the Real-Q 
missed one true positive M. intracellulare in the clinical samples (target sequence; 16S-23S internal transcribed spacer region).
Fig. 1. In-house MTB PCR. Lane 1, size marker; Lane 2, internal control; 
Lane 7, positive; Lane 3-6, 8, negative. MTB, Mycobacterium tuberculosis.
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ture and the acid fast bacilli (AFB) stain. He presented blood-
tinged sputum and multiple haziness in the chest X-ray film. 
Based on clinical manifestation and the PCR result, TB was 
diagnosed.
NTM detection 
By examining 80 clinical samples that were found to be 
negative for NTM on at least one test and 37 DNA samples 
that were provided, we compared the results of the AdvanS-
ure and the Real-Q, which detected NTM. Out of 80 MTB 
negative samples, one sample was identified as positive by 
both kits. It was a sputum sample that was later confirmed 
to contain M. intracellulare by subsequent DNA sequenc-
ing. For 2 other samples of the 80 samples, the two kits 
yielded opposite results; the result from AdvenSure was 
positive while that from Real-Q was negative in both cases 
(Table 4). In one of the pulmonary specimens with NTM 
negative results by 2 PCR methods showed positive in the 
culture and the AFB stain. It was then identified to be M. 
abscessus by PCR-restriction fragment length polymor-
phism (RFLP) in the reference laboratory.6
These clinical samples were further analyzed through 
DNA sequencing, genotyping chip tests, AFB stains, and 
cultures. Interestingly, it was concluded that one sample 
was NTM false positive by AdvanSure, while the other 
scribed spacer (ITS) was sequenced and the results were 
confirmed by a BLAST search. In addition, the AdvanSure 
Mycobacteria Genotyping Chip (LG Lifescience, Seoul, 
Korea) was used in order to reconfirm the results. The Ad-
vanSure Mycobacteria Genotyping Chip implements the 
hybridization method by employing the ITS probe that ex-
ists between the 16S rRNA and 23S rRNA of mycobacteria, 
thereby identifying both MTB and NTM. The chip was used 
according to the manufacturer’s instructions; hybridization 
was conducted after PCR and the results were analyzed 
with the provided insert.
RESULTS
MTB detection 
Out of the 91 clinical samples, there were 75 pulmonary 
samples (64 sputum samples, 11 BAL samples) and 16 non-
pulmonary samples. The results from the two previously im-
plemented PCR methods showed a perfect match for all 91 
samples, including the 11 MTB positive samples. These 
were found to be positive by the other three real-time PCR 
techniques, and 100% concordance was observed among all 
the tests (Table 3). One of the pulmonary specimens that 5 
PCR methods detected MTB showed negative in the TB cul-
Table 3. The MTB PCR Results for 91 Clinical Specimens 
PCR methods Conventional methods
In-house PCR Amplicor* TaqMan† AdvanSure‡ Real-Q§  Cultureǁ AFBǁ
MTB
Positive 11 11 11 11 11 10   7
 Negative 80 80 80 80 80 80 83
MTB, Mycobacterium tuberculosis; AFB, acid fast bacilli.
*COBAS Amplicor MTB (Roche, Indianapolis, IN, USA). 
†COBAS TaqMan MTB (Roche, USA).
‡AdvanSure TB/NTM real-time PCR kit (LG Lifescience, Seoul, Korea).
§Real-Q M. tuberculosis kit (Biosewoom, Seoul, Korea). 
ǁOne of the 91 clinical samples had no culture and AFB stain results.
Table 4. Discrepant Cases for Both the Clinical Specimens and the DNA Samples Provided
Discrepant cases
PCR methods Genotyping methods Conventional methods
AdvanSure Real-Q
Amplicor/
in-house PCR
DNA chip† Sequencing Culture AFB
Clinical 
specimen
1 (TP) NTM + NTM + - / - MIC MIC NTM + -
2 (TP) NTM + NTM - - / - MIC MIC NTM + +
3 (FP) NTM + NTM - - / - - - No growth -
  4 (TP)* NTM - NTM - - / -  Not done Not done NTM + +
M. lentiflavum (DNA) NTM + NTM - Not done MLF Not done Not done
AFB, acid fast bacilli; TP, true positive; FP, false positive; NTM, non-tuberculous mycobacterium; MIC, M. intracellulare; MLF, M. lentifla-
vum.
*It was confirmed to M. abscessus.
†AdvanSure Mycobacteria Genotyping Chip (LG Lifescience, Seoul, Korea).3 Real-Time PCR Kits for Mycobacterium
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bronchoalveolar lavage (BAL), while the latter included 
non-respiratory samples such as body fluid and urine, 
which made up 30.5% of the sample group.13,14 Therefore, 
it is highly possible that one of the causes for the different 
estimates of sensitivity and specificity is the difference in 
the sample composition. In particular, PCR inhibitory mate-
rials in non-respiratory samples can result in a lower sensi-
tivity when performing real-time PCR on those samples.15,16
We found a 100% match of the results for MTB detection 
in a comparative analysis of five PCR methods, as well as 
several discordant results with culture and AFB stain. In one 
of the sputum specimens which showed MTB positive in 
five PCR methods, MTB did not grow and AFB stain re-
vealed no acid fast bacili. Because the patient had the medi-
cal history of TB and showed clinical symptoms and signs 
to be compatible with active TB, the medication for MTB 
was started based on the PCR result. 
There were also a few discrepant results regarding the 
detection of NTM. After detecting NTM in the MTB PCR-
negative clinical samples with the AdvanSure and the Real-
Q, two cases showed mismatching results, while one other 
case turned out to be positive with both kits. In the two mis-
matching cases, the results from the AdvanSure were all 
positive and the results from the Real-Q were all negative. 
The medical records indicated that one of 2 AdvanSure 
positive cases showed a history of NTM TB treatment, and 
the offending organism was later identified to be M. intra-
cellulare by DNA sequencing and genotyping chip tests. 
The other AdvanSure positive case turned out to be TB false 
positive after additional analysis, thus concluding that there 
was one false positive result by the AdvanSure and one 
false negative result by the Real-Q. The false positive sam-
ple in the AdvanSure was a sputum sample from a 13-year-
old male patient who had a history of TB before the age of 
1 and he had undergone a 6-month medication. That patient 
was hospitalized for symptoms of pneumonia, and his spu-
tum test was negative after an AFB stain. Since the patient 
did not have clinical evidence of TB, he was released after 
being treated for bacterial pneumonia. The Ct value for this 
sample was 33.25, which was higher than 27.02 of the in-
ternal control. The sample that turned out to be false nega-
tive in the Real-Q was a sputum sample that continuously 
indicated a positive value of 2+ to 3+ in AFB stain and the 
offending organism had been identified as M. intracellulare 
by culture. Both samples came from patients who were di-
agnosed with NTM-caused TB, with both being identified 
as M. intracellulare and the 2 samples were found negative 
sample was NTM false negative by the Real-Q (M. intra-
cellulare)(Table 4). Therefore, two samples out of 80 clini-
cal samples that were MTB negative were found to be 
NTM positive, representing 2.5% of the total samples (Fig. 
2). In the chart review, these two patients were confirmed to 
have NTM TB as well. 
The 37 DNA samples provided by LG Lifescience were 
used to evaluate these two kits by blind testing. Because 
both kits showed negative for all 6 non-NTM DNA sam-
ples, there were no false positive results. Nevertheless, there 
was one false negative by the Real-Q, which was negative 
for M. lentiflavum. 
c a DISCUSSION
Considering the fact that many laboratories have recently 
implemented real-time PCR assays to detect viruses or fas-
tidious microbes, and that real-time PCR uses a closed sys-
tem, thereby lowering the potential for false positive results 
caused by cross-contamination of the amplified products, it 
is highly expected that the usage of real-time PCR will con-
tinue to increase in the field of microbiological diagnosis.7-9 
In addition, the need to differentiate MTB and NTM is 
gaining more importance, owing to the growing occurrence 
of NTMs and the fact that both MTB and NTM require dif-
ferent medications.2 In the present study, therefore, we 
compared and assessed the diagnostic performance of three 
types of commercial real-time PCR kits for MTB detection 
and NTM differentiation, as well as two PCR methods pre-
viously implemented in our hospital. 
Since the COBAS Amplicor test was shown to have a 
low sensitivity for non-respiratory samples, Kyung Hee 
University Medical Center had been using the Amplicor for 
respiratory samples while in-house PCR was used for non-
respiratory samples.10 In our previous reports, the diagnos-
tic sensitivity and specificity of our in-house PCR method 
were shown to be 81.0% and 99.6%, respectively.11 For the 
COBAS Amplicor, the diagnostic sensitivity varies from 
about 70% to about 80%-90%, depending on the studies.11,12 
One study in Korea showed the sensitivity and the specificity 
of the AdvanSure to be 97.9% and 100%, respectively, 
whereas 91% and 87%, respectively, in the other study, al-
though there are only a fewer reports on the sensitivity and 
specificity of TB detection by real-time PCR.12,13 These two 
studies are different in their sample composition; the former 
used only respiratory samples that comprised sputum and Sun Young Cho, et al.
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multiplex real-Time PCR and melting curve analysis in identifica-
tion of nontuberculous mycobacteria]. Korean J Lab Med 2007; 
27:40-5.
4. Baba K, Pathak S, Sviland L, Langeland N, Hoosen AA, Asjo B, 
et al. Real-time quantitative PCR in the diagnosis of tuberculosis 
in formalin-fixed paraffin-embedded pleural tissue in patients 
from a high HIV endemic area. Diagn Mol Pathol 2008;17:112-7.
5. Lee MF, Chen YH, Peng CF. Evaluation of reverse transcription 
loop-mediated isothermal amplification in conjunction with ELI-
SA-hybridization assay for molecular detection of Mycobacterium 
tuberculosis. J Microbiol Methods 2009;76:174-80.
6. Lee H, Park HJ, Cho SN, Bai GH, Kim SJ. Species identification 
of mycobacteria by PCR-restriction fragment length polymorphism 
of the rpoB gene. J Clin Microbiol 2000;38:2966-71.
7. Flores E, Rodríguez JC, Garcia-Pachón E, Soto JL, Ruiz M, Es-
cribano I, et al. Real-time PCR with internal amplification control 
for detecting tuberculosis: method design and validation. APMIS 
2009;117:592-7.
8. Richardson ET, Samson D, Banaei N. Rapid Identification of My-
cobacterium tuberculosis and nontuberculous mycobacteria by 
multiplex, real-time PCR. J Clin Microbiol 2009;47:1497-502.
9. Mackay IM. Real-time PCR in the microbiology laboratory. Clin 
Microbiol Infect 2004;10:190-212.
10. Tortoli E, Tronci M, Tosi CP, Galli C, Lavinia F, Natili S, et al. 
Multicenter evaluation of two commercial amplification kits (Am-
plicor, Roche and LCx, Abbott) for direct detection of Mycobacte-
rium tuberculosis in pulmonary and extrapulmonary specimens. 
Diagn Microbiol Infect Dis 1999;33:173-9.
11. Yang HY, Lee HJ, Park SY, Lee KK, Suh JT. [Comparison of In-
house Polymerase Chain Reaction Assay with Conventional Tech-
niques for the Detection of Mycobacterium tuberculosis]. Korean J 
Lab Med 2006;26:174-8.
12. Choi YM, Lee MH. Detection of Mycobacterium tuberculosis in 
sputum by using polymerase chain reaction. Korean J Clin Micro-
biol 1999;2:144-51. 
13. Kim YJ, Park MY, Kim SY, Cho SA, Hwang SH, Kim HH, et al. 
[Evaluation of the performances of advanSure TB/NTM real time 
PCR Kit for detection of mycobacteria in respiratory specimens]. 
Korean J Lab Med 2008;28:34-8.
14. Jung CL, Kim MK, Seo DC, Lee MA. Clinical usefulness of real-
time PCR and amplicor MTB PCR assays for diagnosis of tuber-
culosis. Korean J Clin Microbiol 2008;11:29-33.
15. Scarparo C, Piccoli P, Rigon A, Ruggiero G, Scagnelli M, Piersi-
moni C. Comparison of enhanced Mycobacterium tuberculosis 
amplified direct test with COBAS AMPLICOR Mycobacterium 
tuberculosis assay for direct detection of Mycobacterium tubercu-
losis complex in respiratory and extrapulmonary specimens. J Clin 
Microbiol 2000;38:1559-62.
16. Goessens WH, de Man P, Koeleman JG, Luijendijk A, te Witt R, 
Endtz HP, et al. Comparison of the COBAS AMPLICOR MTB and 
BDProbeTec ET assays for detection of Mycobacterium tuberculo-
sis in respiratory specimens. J Clin Microbiol 2005;43:2563-6.
by the TaqMan. Among NTM PCR-negative samples in the 
AdvanSure and the Real-Q, there was a sputum specimen 
that showed positive in the culture and the AFB stain. We 
referred the NTM identification to the reference laboratory, 
and it was identified to be M. abscessus.6 In conclusion, 
three NTM true-positive results out of 80 MTB negative 
samples (2.5%) were confirmed. As for 37 DNA samples, 
the AdvanSure and the Real-Q recognized 6 non-NTM 
DNA (MTB, nocardial and rhodococcal DNA) as negative, 
while the Real-Q recognized M. lentiflavum as negative out 
of 31 NTM DNA samples. Considering these results, the im-
plementation of real-time PCR methods that are capable of 
NTM differentiation made it possible to make a swift and 
accurate diagnosis of NTM TB.
In conclusion, the five kits included in this comparative 
analysis yielded good matching ratios for the MTB detec-
tion results. However, for detecting NTM, there was some 
discordance, therefore, further confirmatory measures such 
as DNA sequencing, a medical record review, and/or cul-
ture are required in order to make an accurate diagnosis. 
Future research on this topic is certainly needed, and this 
research would be benefited from the putatively increased 
NTM detection capacities to assess numerous and varied 
samples, including non-respiratory samples or negative 
samples in ATB stain.
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